In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|August 18, 2020
Information Systems in Clinical Trials: Pragmatic Validation of EDC Systems
Author(s)Elsevier
Join us as we explore system validation with Will Crocombe from RISG Consulting, and share practical ways to address change overload and survive a visit from the inspectors. Live: Thursday, Sept. 17, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST On demand available after airing until Sept. 17, 2021.
Register free:
Event Overview:
Computer System Validation is a key regulatory requirement and one which challenges the understanding and resources of many research organizations. Achieving the validated state means managing an ever-changing environment of servers, operating systems, EDC software, security patches etc, some or all of which may be outside the direct control of the organization. And all this needs considering before you have even started developing your study database.
GCP expects a risk-proportionate approach, but how can this be approached, pragmatically?
During this webcast we’ll explore the scope of EDC system validation and offer practical ways of dealing with change overload and surviving a visit from the inspectors.
Key Learning Objectives:
Join us for this webcast to:
- Understand the scope of system validation and the challenges this brings
- Discover an approach to unpicking the complexity
- Have an opportunity to discuss practical solutions
Speakers: Will Crocombe, Director, RISG Consulting, UK
Oli Cram, Macro General Manager, Elsevier
Time and date: Thursday, Sept. 17, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
On demand available after airing until Sept. 17, 2021.
Sponsor: Elsevier
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5